12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Belinostat regulatory update

Topotarget said the European Commission granted Orphan Drug designation for belinostat to treat malignant thymomas. The product is in a National Cancer Institute (NCI)-led Phase II...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >